WebJun 1, 2024 · Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease … WebJan 7, 2024 · Akebia Therapeutics (NASDAQ:AKBA -64.1%) shares have reached a historic low on Wednesday after the Cambridge, Massachusetts-based biotech announced that the U.S. Food and Drug Administration (FDA) declined to approve its marketing application for the kidney disease therapy vadadustat. Tell Me More › Will AKBA stock recover? › Stock …
FDA to review Akebia’s and Otsuka’s vadadustat for anemia …
WebApr 11, 2024 · A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and … WebMar 7, 2024 · Approval of Bristol-Myers’ drug for multiple uses in immune-oncology cases could add $437 million to the company’s top line in 2026, Evaluate reported. The combination of the drug pending approval, relatlimab, with Opdivo held off cancer progression by 10.1 months as opposed to Opdivo by itself, which was effective for just … lock up switch cummins
Akebia and partner Otsuka seeks EU nod for drug to treat anemia …
WebApr 11, 2024 · The Akebia Therapeutics stock price gained 3.19% on the last trading day (Monday, 3rd Apr 2024), rising from $0.560 to $0.578. During the last trading day the … WebApr 13, 2024 · Probable time of next FDA approval: Unknown Probable time of next financing: Unknown. TG Therapeutics (TGTX – $20.15) moved up after Cantor Fitzgerald said their new multiple sclerosis drug, Briumvi, experienced a “solid jump” in March sales to $3.3 million from $0.5 million in February. That means total first-quarter sales were about … WebJun 1, 2024 · FDA has accepted a new drug application (NDA) for the oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor vadadustat from Akebia Therapeutics (NSDQ:AKBA) and its partner Otsuka Pharmaceutical Co. (TYO:4578). The two companies are pursuing the use of the drug to treat anemia resulting from chronic kidney disease. indigestion and heart failure